Sumeet Sud shares news about Pharmaceutical Companies License Agreement

Theravance Biopharma Ireland Limited, and Pfizer announced the companies have entered into a global license agreement for Theravance Biopharma’s preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitor that can be rapidly metabolized. The compounds in this program target validated pro-inflammatory pathways and are specifically designed to process skin-selective activity with minimal systemic exposure.